California's Boreal Genomics pulled in an $18 million Series C financing to back further commercial growth of its genomic research tools and diagnostic test business. The Los Altos company sells research tools and develops diagnostic tests focused on noninvasive tumor profiling and cancer monitoring. A core focus: genomic analysis of tumor-derived circulating nucleic acids in blood. And execs want to roll out new blood-based diagnostic tests to help detect and monitor disease. Existing investors ARCH Venture Partners and Kearny Venture Partners participated in the new round, which also attracted unnamed strategic and private investors. Boreal launched in 2007 and employs about 40 people. Story